Dodecafluoropentane emulsion decreases infarct volume in a rabbit ischemic stroke model

Journal of Vascular and Interventional Radiology

Volumn 23, Issue 1, 2012, Pages 116-121

  Culp, William C ^a   Woods, Sean D ^a   Skinner, Robert D ^a   Brown, Aliza T ^a   Lowery, John D ^b   Johnson, Jennifer L H ^c   Unger, Evan C ^c   Hennings, Leah J ^a   Borrelli, Michael J ^a   Roberson, Paula K ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERFLUOROPENTANE;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; BRAIN SIZE; BRAIN WEIGHT; CONTROLLED STUDY; EMULSION; EUTHANASIA; EXPERIMENTAL RABBIT; INTERNAL CAROTID ARTERY; NEUROPROTECTION; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; STAINING; STROKE; TISSUE SECTION;

ANIMALS; CEREBRAL ANGIOGRAPHY; CEREBRAL HEMORRHAGE; CHI-SQUARE DISTRIBUTION; DISEASE MODELS, ANIMAL; EMULSIONS; FLUOROCARBONS; RABBITS; RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84855347068     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2011.10.001     Document Type: Article

References (25)

1. Jurga JJ, Nyman J, Tornvall P, et al. Cerebral microembolism during coronary angiography. Stroke 2011; 42:1475-1477.
2. Kim HW, Greenburg AG. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Artif Organs 2004; 28:813-828. (Pubitemid 39159154)
3. Pignataro G, Simon P, Xiong ZG. Prolonged activation of ASIC1a and the time window for neuroprotection in cerebral ischaemia. Brain 2007; 130:151-158. (Pubitemid 46026231)
4. Donnan GA. The 2007 Feinberg Lecture: a new road map for neuroprotection. Stroke 2008; 39:242-248.
5. Fergusson DA, McIntyre L. The future of clinical trials evaluating blood substitutes. JAMA 2008; 299:2324-2326. (Pubitemid 351724402)
6. Vinukonda G, Csiszar A, Hu F, et al. Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. Brain 2010; 133:2264-2280.
7. Liesz A, Zhou W, Mracskó É, et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 2011; 134:704-720.
8. Reiss JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2005; 33:47-63.
9. Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: Fluorocarbon emulsions and haemoglobin solutions. Br Med Bull 1999; 55:277-298. (Pubitemid 29243562)
10. Correas JM, Quay SC. EchoGen emulsion: a new ultrasound contrast agent based on phase shift colloids. Clin Radiol 1996; 51(Suppl 1):11-14.
11. Johnson JLC, Dolezal MC, Kerschen A, Matsunaga TO, Unger EC. In vitro comparison of dodecafluoropentane (DDFP), perfluorodecalin (PFD), and perfluoroctylbromide (PFOB) in the facilitation of oxygen exchange. Artif Cell Blood Substitutes 2009; 37:156-162.
12. Correas JM, Meuter AR, Singlas E, Kessler DR, Worah D, Quay SC. Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography. Ultrasound Med Biol 2001; 27:565-570. (Pubitemid 32479147)
13. Culp BC, Brown AT, Erdem E, Lowery J, Culp WC. Selective intracranial magnification angiography of the rabbit: basic techniques and anatomy. J Vasc Interv Radiol 2007; 18:187-192. (Pubitemid 46616694)
14. Brown AT, Skinner RD, Flores R, et al. Stroke location and brain function in an embolic rabbit stroke model. J Vasc Interv Radiol 2010; 21:903-909.
15. Flores R, Hennings LJ, Lowery JD, Brown AT, Culp WC. Microbubble- augmented ultrasound sonothrombolysis decreases intracranial hemorrhage in a rabbit model of acute ischemic stroke. Invest Radiol 2011; 46:419-424.
16. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230:1289-1292. (Pubitemid 16194539)
17. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfate N-oxide (generic NCY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002; 33:1411-1415. (Pubitemid 34517068)
18. Diener HC, Lees KR, Lyden P, et al. SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 2008; 39:1751-1758.
19. Lundgren CEG, Bergoe GW, Tyssebotn IM. Intravascular fluorocarbon- stabilized microbubbles protect against fatal anemia in rats. Artif Cell Blood Substitutes 2006; 34:473-486. (Pubitemid 44221664)
20. McKhann GM, Grega MA, Borowicz LM Jr, Baumgartner WA, Selnes OA. Stroke and encephalopathy after cardiac surgery, an update. Stroke 2006; 37:562-571. (Pubitemid 43732027)
21. Grayburn PA, Erickson JM, Escobar J, Womack L, Velasco CE. Peripheral intravenous myocardial contrast echocardiography using a 2% dodecafluoropentane emulsion: identification of myocardial risk area and infarct size in the canine model of ischemia. J Am Coll Cardiol 1995; 26:1340-1347.
22. Brown AT, Flores R, Hamilton E, Roberson PK, Borrelli MJ, Culp WC. Microbubbles improve sonothrombolysis in vitro and decrease hemorrhage in vivo in a rabbit stroke model. Invest Radiol 2011; 46:202-207.
23. Zhao BQ, Suzuki Y, Kondo K, Ikeda Y, Umemura K. Combination of a free radical scavenger and heparin reduces cerebral hemorrhage after heparin treatment in a rabbit middle cerebral artery occlusion model. Stroke 2001; 32:2157-2163. (Pubitemid 32868116)
24. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit, Press release from the 40th Plenary Meeting of the Committee for Proprietary Medicinal Products. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Press-release/2009/12/WC500017427.pdf. Accessed March 1, 2010.
25. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit, Withdrawal of the marketing authorization for the medicinal product EchoGen - dodecafluoropentane. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Public-statement/2009/12/ WC500018334.pdf. Accessed March 1, 2010.